Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo Adjuvant Chemotherapy (NAC) for Breast Cancer.

Overview

The purpose of this study is to determine the number of participants who can handle the treatment within specific safety parameters, determine the number of participants who can handle safely the maximum tolerated dose (MTD) (within 50-200 mg/BID dose range) when combining Veliparib and radiation, as well as to identify side effects and their intensity at different dosing levels.

Description

The purpose of this study is to identify the side effects, if any, when radiation and Veliparib are given together to treat women who still have cancer in their breast or under arm lymph nodes after being treated with pre-surgery chemotherapy.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: breast cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Female

Inclusion Criteria
Patients must have histologically confirmed (by routine H&E staining) adenocarcinoma of the breast with confirmed nodal metastasis
Patients must have an axillary nodal evaluation by fine needle aspiration (FNA), sentinel node biopsy (SNB) or nodal dissection
Patient must have had a bilateral mammogram prior to NAC unless there is only one breast
Patient must have a Medical Oncology consult and be recommended to receive neoadjuvant chemotherapy for a stage IIB through IV carcinoma
Patients must not have received prior radiation therapy to the involved breast at any time for any reason
Patient must have a history and physical within 2 weeks prior to the start of any protocol therapy (radiation and veliparib)
Patient must have > 1.0 cm residual in-breast cancer and/or clinically positive residual nodal disease
No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years
Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment
Patients must have a performance status 0 or 1 by ECOG criteria (Appendix I)
Exclusion Criteria
Patients with squamous, or metaplastic carcinomas or sarcomas of the breast
Women who have a investigational therapy, was less than 14 days prior to protocol therapy (radiation and veliparib)
Bisphosphonates, hormone modification therapy, and trastuzumab are permitted without restriction
Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment
Pregnant or breast-feeding
Clinically significant and uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or neurological/psychiatric disease or disorder
Unable to swallow and retain oral medications
History of seizure disorder
Known contraindication to enhanced MRI and CT
Previous enrollment on another study involving the investigation of veliparib (ABT- 888), with the exception of receiving a single dose of study drug
Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive veliparib (ABT-888) and/or breast irradiation


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022 . Study ID: TX5475

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center